CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Immix Biopharma, Inc.

IMMX
$862MSmall Cap

Next catalyst

Phase 2December 2026

NXC-201 CAR-T

Light Chain (AL) Amyloidosis

Get an email about IMMX's next catalysts

Track Immix Biopharma (IMMX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 1 more upcoming event in our data (earnings).See the timeline

Catalyst Timeline

2 upcoming, 2 past

Earnings

IMMX Earnings Report

Dec 14, 2026

Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.18 | FQ end Sep/2026 | Call: tbd

Phase 2Next

NXC-201 CAR-T Phase 2 Est. Readout (NEXICART-2)

December 2026~NXC-201 CAR-T45

Estimated primary completion for NXC-201 CAR-T trial (NCT06097832) in Light Chain (AL) Amyloidosis. Topline data typically follows completion by weeks to months.

Source

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical PreparationsπŸ‡ΊπŸ‡ΈNorth AmericaLOS ANGELES18 employees
Drug Pipeline

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

Frequently asked questions

What is in Immix Biopharma, Inc.'s drug pipeline?β†’

CatalystAlert tracks 1 drug candidate in Immix Biopharma, Inc.'s (IMMX) pipeline across Phase 2. Its lead program is NXC-201 CAR-T (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Immix Biopharma, Inc.'s next FDA catalyst?β†’

Immix Biopharma, Inc.'s (IMMX) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track IMMX biotech catalysts?β†’

Add IMMX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Immix Biopharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β€” sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply